FDA Approved: SYLVANT — Supplemental Application (Recordati Rare Diseases, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Sylvant (siltuximab) submitted by Recordati Rare Diseases, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multicentric Castleman Disease

Drugs mentioned

• Sylvant (siltuximab)

Snippet

SUPPL AP for SYLVANT (SILTUXIMAB)